FACE MAKE-UP BODY
CERAMIDE 2
BARRIER
Ceramide 2
REPAIR
Function:
Restructuring function
Maintains moisture and integrity of the
cutaneous barrier.
Definition:
Ceramide 2 is a pure substance
identical to natural ceramides
constituting 40-50% of the
skin’s lipids.
Properties:
Captures and retains the water
necessary for the epidermal
equilibrium.
Fights against skin ageing and
preserves the skin’s youth.
Origin:
Synthetic.
INCI name:
Ceramide NG
Applications:
Make-up products, skin and body care,
dry skin treatments, aged skin.
Formulation:
Heat ceramide 2 with emulsifier
up to 90°C.
Add the oily phase after
heated to 75°C.
Heat water phase to 75°C and emulsify.
Recommended use level:
Attack treatment (very dry skin):
0.2 to 1% (pure powder)
Maintenance treatment
0.05 to 0.2% (pure powder)
WATER
2 to 10% (sol at 2%) RETENTION
Patent: WATER
WO 1998/07744
RETENTION
INTEGRITY WATER INTEGRITY
www.sederma.com OF THE SKIN RETENTION OF THE SKIN
E-mail: sederma@sederma.fr
Copyright© 1995-2014
Sederma. All rights reserved.
Member of Croda International Plc
CLAIM SUBSTANTIATION 08-2014
In vivo tests
Water retention capacity of Ceramide 2 D0 - Before
Water retention capacity
treatment
8th day of treatment
5 volunteers with dry skin. Twice daily application for 8 days of a 33
measured in the epidermis
cream containing 1% Ceramide 2 on the forearm versus placebo.
32
Relaxation times
Measurement of the epidermal water content by MRI (Magnetic Δ T2 increase x 3
31
Resonance Imaging).
30
29
Ceramide 2 captures and retains the water that 1% CERAMIDE 2
28
the epidermis needs in order to stay supple, Placebo
smooth and moisturised. 27
T0 0.5 1 2 3 4 5 6 7 Time (hour)
Restructuring effect of Ceramide 2
Study on short term : 2 hours
Restructuring effect - Short term
13 volunteers with dry skin. 1 application of an emulsion containing 5
1% Ceramide 2 versus placebo after total delipidation (destruction of T = 15’
the cutaneous barrier). 4 T = 2h
Measurement of the TEWL (Trans Epidermal Water Loss) with *: p < 0.05
TEWL (g/m²/h)
3
Tewameter 2 hours after application. -13%
2 -16%
-22%* n.s
TEWL decrease -22%
1
Ceramide 2 leads to a rapid and efficient repair
0 Ceramide 2
of the cutaneous barrier. Control Placebo
Study on medium term : 21 days 5 Restructuring effect - Medium term
CERAMIDE 2
6 volunteers. Daily application of a cream containing 0.5%
Ceramide 2 against placebo for 3 weeks on the forearm. 4
Placebo
Measurements of the TEWL with a Tewameter after stripping. 3
TEWL (g/m²/h)
-51%
TEWL decrease -51% 2
1
The structure of the epidermis is reinforced and
resists better to aggressions. 0
T0 T21 days
Formulation Cream with Ceramide 2 Indicative formula ref: SED 0101115 A
Part A .................................................................................................. % Part E .................................................................................................%
Water Deionised qs 100 Potassium Sorbate 0.10
Ultrez 10 (Carbomer) 0.40
Part F .................................................................................................%
Part B .................................................................................................% Sodium Hydroxide 30% 0.40
Glycerin 5.00 Water Deionised 4.00
Preservative 0.80
Part G .................................................................................................%
Part C .................................................................................................% Fragrance 0.10
Span 60 (Sorbitan Stearate, Croda) 2.00
Crodamol CSO (Cetearyl Octanoate, Croda) 7.00
Protocol
Part D .................................................................................................% Weigh Part A and allow to swell for 20 minutes. Mix Part B and add it to Part A. Then heat Part
Arlacel 170 (Glyceryl Stearate, PEG-100 Stearate, Croda) 3.00 A+B to 75°C in waterbath. Weigh Part C and heat to 75°C in water-bath. Weigh Part D and heat
CERAMIDE 2 (Sederma) 0.20 to 90°C until dissolution. Pour Part D and Part C into Part A+B with staro stirring. Add Part E.
Neutralize with Part F. Add Part G at about 35°C. Homogenize well.
Non-guarantee:
This formulation has been subjected to limited stability tests and has been shown to perform well. However formulators adopting this approach should ensure to their own satisfaction long term stability and functionality. It is good practice to conduct safety tests on all final formulations prior
to marketing. Suggested uses should not be taken as an inducement to infringe any existing patents.
v. 140821
Non-guarantee: The information in this publication is given in good faith by Sederma by way of general guidance and for reference purposes only. The information should not be construed as granting a license to practice any methods or compositions of matter covered by patents. Sederma assumes
no liability in relation to the information and gives no warranty regarding the suitability of the product and/or ingredients described for a particular use. The use made of the product and/or ingredients described by the recipient and any claims or representations made by the recipient in respect of
such product and/or ingredients are the responsibility of the recipient. The recipient is solely responsible for ensuring that products marketed to consumers comply with all relevant laws and regulations.
Reproduction of all or part of this document without the express prior written consent of Sederma is strictly prohibited.
Sederma 29 rue du Chemin Vert 78612 Le Perray-en-Yvelines cedex France Tel. : +33 (0)1 34 84 10 10 Fax : +33 (0)1 34 84 11 30
